Use of Statins and Aspirin to Reduce Risks of Cardiovascular Disease

1. Hebert PR , Gaziano JM , Chan KS , Hennekens CH . Cholesterol lowering with statin drugs, risk of stroke and total mortality. JAMA 278:313-321, 1997

2. Hennekens CH . Aspirin in the treatment and prevention of cardiovascular disease. Annu Rev Public Health 18:37-49, 1997

3. Hebert PR , Hennekens CH . An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. Arch Intern Med 160:3123-3127, 2000

4. Steinberg D , Gotto AM . Preventing coronary artery disease by lowering cholesterol levels: Fifty years from bench to bedside. JAMA 282:2043-2050, 1999

5. Vane JR . Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231:232-235, 1971

6. Sacks FM , Pfeffer MA , Moye LA , et al, for the Cholesterol and Recurrent Events Trial Investigators . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1019, 1996

7. Ridker PM , Rifai N , Pfeffer MA , et al, for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:839-844, 1998

8. Ridker PM , Rifai N , Pfeffer MA , Sacks F , Braunwald E , for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100:230-235, 1999

9. Ridker PM , Rifai N , Clearfield M , et al for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965, 2001

10. Albert M , Danielson E , Rifai M , Ridker PM , for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels. JAMA 286:64-70, 2001

11. Ridker PM , Cushman M , Stampfer MJ , Tracy RP , Hennekens CH . Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997

12. Ridker PM , Hennekens CH , Buring JE , Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843, 2000

13. Ikonomidis I , Andreotti F , Economou E , Stefanadis C , Toutouzas P , Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100:793-798, 1999

14. Cook NR , Hebert PR , Manson JE , Buring JE , Hennekens CH . Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the Physicians' Health Study. Arch Intern Med 160:921-928, 2000

15. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 339:1349-1357, 1998

16. The WOSCOPS Study Group . Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol 76:485-491, 1995

17. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994

18. Downs JR , Clearfield M , Weis S , et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 279:1615-1622, 1998

19. Hennekens CH , Buring JE , Sandercock P , Collins R , Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80:749-756, 1989

20. Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002

21. Hennekens CH , Dyken ML , Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 96:2571-2573, 1997

22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001

23. Pearson TA , Laurora I , Chu H , Kafonek S. The lipid treatment assessment project (L-TAP). Arch Intern Med 160:459-467, 2000

24. Sanmuganathan PS , Ghahramani P , Jackson PR , Wallis EJ , Ramsay LE . Aspirin for primary prevention of coronary heart disease. Heart 85:265-271, 2001